US20180369603A1 - Device for photodynamic treatment - Google Patents

Device for photodynamic treatment Download PDF

Info

Publication number
US20180369603A1
US20180369603A1 US16/063,203 US201616063203A US2018369603A1 US 20180369603 A1 US20180369603 A1 US 20180369603A1 US 201616063203 A US201616063203 A US 201616063203A US 2018369603 A1 US2018369603 A1 US 2018369603A1
Authority
US
United States
Prior art keywords
balloon
catheter device
light
distal end
hollow organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/063,203
Other languages
English (en)
Inventor
Tore Gjørsvik
Aslak Godal
Roger William Rolfe Warren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASA filed Critical Photocure ASA
Assigned to PHOTOCURE ASA reassignment PHOTOCURE ASA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GJØRSVIK, Tore, GODAL, ASLAK
Assigned to PHOTOCURE ASA reassignment PHOTOCURE ASA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TRITEQ LTD.
Publication of US20180369603A1 publication Critical patent/US20180369603A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
    • A61B5/202—Assessing bladder functions, e.g. incontinence assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/02—Holding devices, e.g. on the body
    • A61M25/04—Holding devices, e.g. on the body in the body, e.g. expansible
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1018—Balloon inflating or inflation-control devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0642—Irradiating part of the body at a certain distance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes

Definitions

  • This invention relates to a device for use in the photodynamic treatment of a body cavity or hollow organ of the body, such as the bladder, and to the use of such a device in the photodynamic treatment of abnormalities, disorders or diseases of the internal surfaces of said body cavity or hollow organ.
  • Photodynamic treatment is a relatively new technique for the treatment of pre-cancerous conditions, cancer and non-cancerous diseases, such as infections and inflammation.
  • PDT involves the administration of a photosensitiser or a precursor thereof to an area of interest.
  • the photosensitiser or precursor thereof is taken up into the cells, where a precursor of a photosensitiser is converted into a photosensitiser.
  • the photosensitiser Upon exposure of the area of interest to light, the photosensitiser is excited, usually from a ground singlet state to an excited singlet state. It then undergoes intersystem crossing to a longer-lived excited triplet state.
  • One of the few chemical species present in tissue with a ground triplet state is molecular oxygen.
  • Typical photosensitisers include dyes like hypericin and PVP hypericin, psoralens, porphyrins such as hematoporphyrins, protoporphyrins, uroporphyrins, coproporphyrins, benzoporphyrins or deuteroporphyrins, in particular Photofrin® (porfimer sodium), photosan III or verteporfin; chlorins, including bacteriochlorins and isochlorins such as chlorine e6, talaporfin or temoporfin and phthalocyanines such as aluminium- and silicon phthalocyanines.
  • Typical precursors of photosensitisers include 5-aminolevulinic acid (5-ALA) and certain derivatives thereof, e.g. 5-ALA N-derivatives or 5-ALA esters.
  • 5-ALA 5-aminolevulinic acid
  • Such compounds are intracellularly converted protoporphyrins, such as protoporphyrin IX (PpIX), which are photosensitisers.
  • protoporphyrin IX PpIX
  • Currently several pharmaceutical products comprising 5-ALA or 5-ALA esters are in clinical use for PDT.
  • Metvix® a topical dermal product in the form of a cream comprising 5-ALA methyl ester (Galderma, Switzerland) for the photodynamic treatment of actinic keratosis and basal cell carcinoma.
  • Levulan Kerastick® DUSA Pharmaceuticals, Canada
  • a solution for the photodynamic treatment of actinic keratosis which contains 5-ALA.
  • 5-ALA, 5-ALA hexyl ester and several other photosensitisers such as Photofrin® have been used experimentally in pre-clinical and clinical studies for the photodynamic treatment of bladder cancer (for review: N. Yavari et al., Can J Urol. 2011, 18(4), 5778-86).
  • Standard therapies are based on resection of cancerous lesions via transurethral bladder resection (TUR) and/or fulguration of all visible tumours, in association with different modalities of topical chemo- or immunotherapy, i.e. agents that are instilled into the bladder such as mitomycin C or bacillus Calmette-Guérin (BCG).
  • TUR transurethral bladder resection
  • BCG bacillus Calmette-Guérin
  • the inner surface of the bladder i.e. the bladder wall
  • rugae The inner surface of the bladder, i.e. the bladder wall
  • the function of the rugae is to allow the bladder to expand when needed.
  • the rugae are folds in the tissue.
  • the bladder fills with urine, it expands by unfolding the rugae.
  • the rugae When the bladder empties again, it refolds and the rugae increase to their former size.
  • these rugae present a challenge since the whole bladder wall needs to be exposed to light such that no cancerous lesions are missed.
  • a catheter is equipped with a Foley balloon for securing the catheter in the bladder and an optical fibre supplies light to a scattering rod intended to distribute light across the internal surface during irrigation with saline to keep the surface smooth.
  • Another proposal (W. Beyer, Journal of Photochemistry and Photobiology B: Biology 36 (1996) 153-156) uses a light applicator for bladder PDT using two concentric transparent balloons. An outer balloon, inflated by water, fills the bladder and touches the outer wall, stretching it to a smooth surface. An inner balloon is filled with a fat emulsion as a scattering medium and distributes light from an optic fibre with a conical end.
  • the light passing through the prior art optic fibres will always be travelling generally along the longitudinal axis of the catheter in the forward direction, i.e. in a distal direction along the direction of the longitudinal axis.
  • projecting light in all directions to provide coverage throughout the entirety of the inner surface of the body cavity or hollow organ requires a relatively complex redistribution of the direction of the light and illumination of the inner surface at the entrance to the body cavity or hollow organ is difficult to achieve.
  • the device proposed above by placing a light source within the body and by the use of a plurality of light emitting elements located in different regions then it becomes possible to direct light in all of the required directions, including at the entrance to the hollow organ or body cavity, with a very even distribution and with a relatively simple design.
  • light emitting elements placed within the body in this way can easily provide the required wavelengths and intensity of light whilst remaining very compact and therefore able to be used by a catheter device even when a relatively small catheter is used, for example for treatment of the bladder and approaching via the urethra.
  • the device can also be sufficiently small and flexible to allow for use with just a local anaesthesia, rather than a general anaesthesia (which is required for larger and more rigid devices).
  • the light source required to generate the required wavelengths at the necessary intensity through transmission along the optic fibre would generally need to be a laser or a high-powered xenon short arc lamp, for example.
  • this is a relatively complex item of equipment and often would not be readily available to medical staff, as well as requiring extra training, safety precautions and/or safety equipment.
  • the present invention provides a catheter device for use in the photodynamic treatment of a body cavity or hollow organ of the body, the catheter device comprising: a distal end portion having a longitudinal axis and being for insertion into the body cavity or hollow organ, the distal end portion including: an expansion and positioning balloon for expanding within the body cavity or hollow organ and thereby distending an outer wall of the body cavity or hollow organ, and a light source located on the distal end portion so as to be within the body cavity or hollow organ when the catheter device is in use; wherein the light source comprises a plurality of light emitting elements arranged to: project light forward in a distal direction along the direction of the longitudinal axis from a first region of the distal end, project light outwardly of the longitudinal axis from a second region of the distal end, the second region being at least partly within the expansion and positioning balloon, and project light around the point of entry of the catheter device into the body cavity or hollow organ from a third region of the distal end, the third region being closer to the
  • these safe temperatures can be maintained simply based on the available heat absorption within the body cavity or hollow organ of interest and the heat dissipation to the rest of the body that is possible.
  • heat may optionally be removed by means of the catheter device, for example through exchange of liquids with the outside of the body, and/or cooling may be provided before treatment, for example by use of fluids at below body temperature to expand the positioning and expansion balloon.
  • WO 2015/006309 a device is discussed primarily in context of light transmitted via an optical fibre system, but mention is also made of the possible use of light emitters within the body such as LEDs, although without any discussion of refinements as set forth herein.
  • the device or WO 2015/006309 may include a single balloon for inflation to position light delivery elements at a minimum distance from a target tissue.
  • the device of the first aspect set out above differs in significant respects from the device of WO 2015/006309 through the use of a specific arrangement of light emitting elements in different regions, with particular purposes, and via the combination of this with the use of two balloons, where an expansion and positioning balloon at least partly contains the second region of the light emitting elements, and a separate second balloon is provided for retaining the device within the body cavity or hollow organ.
  • the expansion and positioning balloon advantageously allows for correct positioning of the device within the body cavity or hollow organ and a suitable distance between body tissue and the light emitting elements, whilst the separate second balloon can retain the distal end within the body cavity or hollow organ with or without inflation of the expansion and positioning balloon.
  • the proposed device can be operated in various modes including only the second balloon inflated, or with both balloons inflated, such as for flushing of the body cavity or hollow organ before or after treatment, instillation of photosensitiser, photodynamic treatment and so on, as discussed in more detail below.
  • the expansion and positioning balloon may be arranged to centre the device in relation to the expanded shape of the hollow organ or body cavity such that there can be a required minimum light dose for all parts of the interior of the hollow organ or body cavity, and optionally an even light dose across all parts thereof.
  • the expansion and positioning balloon may also act as a safety device, ensuring sufficient distance between the light emitting elements and the body tissue and preventing over-heating and/or an overdose of light.
  • the proposed device is therefore considered to be able to provide improved PDT through better distribution of light, as well as increased ease-of-use and reduced inconvenience to the patient.
  • the device can be used by medical personnel with conventional training in the use of catheters and in an outpatient setting, for example at a urology clinic for treatment of the bladder. As noted above, only local rather than general anaesthesia is required.
  • distal refers to a direction away from the physician (or other medical personnel using the device), which is also the direction of insertion of the device into the body.
  • the “proximal” direction is hence the direction toward the physician, and the direction toward the opposite end of the device to the distal end.
  • the distal end might typically have a generally cylindrical body with the light source and the expansion and positioning balloon located within or on the cylindrical body along with other parts of the device.
  • the longitudinal axis of the distal end of the proposed device would typically be aligned with the longitudinal axis of the catheter and thus would generally extend tangentially from the tubular body structure through which the catheter device is inserted into the body cavity or hollow organ, for example the urethra when the bladder is being treated.
  • the catheter device may be a steerable catheter device and/or may have a curved end for improved access to the body cavity organ of interest.
  • the longitudinal axis of the distal end may differ from the longitudinal axis of the catheter.
  • a Coude catheter type arrangement may be used for ease of access to the male bladder past the prostate.
  • the plurality of light emitting elements of the light source are arranged to project light forward in a distal direction along the direction of the longitudinal axis from the first region of the distal end; project light outwardly of the longitudinal axis from the second region of the distal end; and project light around the point of entry of the catheter device into the body cavity or hollow organ from the third region of the distal end.
  • the plurality of light emitting elements may include one or more light emitting element(s) located at the first region, the second region and/or the third region.
  • the light emitted from the first, second, and/or third region may be produced by light emitting elements located elsewhere on the distal end with light guiding devices such as lenses and/or reflectors being arranged to direct the light to the required region(s) and project the light in the required direction(s).
  • the plurality of light emitting elements includes at least one light emitting element at each of the first region, the second region and the third region, with the light emitting element(s) located at each region providing the light from that region.
  • body cavity/hollow organ refers to such cavities/organs that have non-smooth surfaces or rugae. This includes the vagina, the stomach, the intestines, the bladder and the gallbladder, and preferably refers to the bladder.
  • body cavity/hollow organ should preferably be understood to exclude blood vessels, and hence in preferred embodiments the device is not for treatment of blood vessels.
  • this device will be of particular use in treatment of the bladder.
  • the proposed device will eliminate the need for liquid (e.g. saline) to distend the bladder wall in PDT as well as improving the distribution of light and the ease of the treatment of the bladder.
  • the device is for treatment of the bladder.
  • Saline may still be instilled to the bladder (or other body organ) for cooling purposes or for “lubrication” in that the saline can ease the friction between the balloon and the bladder wall, but saline is not needed for distension of the bladder.
  • the catheter device can be designed as a single use device with all parts in patient contact being disposable.
  • the catheter device is a disposable single use device. This may apply not only to the distal end portion of the device with the features described above, but also to parts of the proximal end of the catheter device, such as the power source, control circuitry, and/or fluid couplings and fluid propulsion devices as described in further detail below.
  • the light source will generally be electrically powered, with power being transmitted via electrical wires along the catheter from a power source outside of the body.
  • the light source is powered by a battery or low voltage power source outside of the body.
  • the plurality of light emitting elements may be any suitable light emitting elements able to produce light at the required intensity and wavelength for the PDT of interest.
  • Absorption spectra from photosensitisers known in the art are available in the literature, e.g. the absorption spectrum of PpIX, the photosensitiser which is the result of cellular conversion of precursors like 5-ALA or derivatives of 5-ALA, like 5-ALA esters, is disclosed in for instance U.S. Pat. No. 6,645,230, FIG. 9.
  • N. Yavari et al., Can J Urol 18(4), 2011, 5778-5786 provide in Table 1 an overview over the main activation wavelength of various photosensitisers and precursors of photosensitisers.
  • irradiation with wavelengths of light in the range of 300-800 nm, e.g. 400-700 nm and 500-700 nm has been found particularly effective and the light emitting elements may hence be selected for light at these wavelengths.
  • Red light 600-670 nm
  • red light is known to penetrate well into tissue and the use of red light in the PDT procedure may thus be useful to destroy abnormalities, e.g. neoplastic tissue, in deeper tissue layers.
  • blue light 400-500 nm
  • green light 500-560 nm
  • different wavelengths may be used to efficiently destroy superficial and deeper lesions.
  • white light irradiation has been used in bladder PDT with precursors like 5-ALA or derivatives of 5-ALA, like 5-ALA esters (see for instance A. Johansson et al., Proc. of SPIE Vol. 7380, 73801S1-S9, 2009 or R. Waidelich et al., Urology 2003, 61(2), 332-337).
  • the light emitting elements may be arranged to produce light with a wavelength in the range 600-670 nm, for example a wavelength of about 635 nm.
  • the light source may project light to the walls of the hollow organ or body cavity of interest with fluence rates of no more than 100 mW/cm 2 , and optionally 50 mW/cm 2 or less, such as a fluence rate in the range 10-35 mW/cm 2 , for example a fluence rate of perhaps about 15-25 mW/cm 2 .
  • the timing of the treatment may be set in order to provide a light dose of 10 J/cm 2 to 100 J/cm 2 . These types of fluence rates and light doses would provide effective PDT for the bladder and similar organs.
  • LEDs light emitting diodes
  • LEDs can provide a cheap and effective light source for the types of wavelengths and intensities that are required for a safe and efficient PDT, as well as being available in sufficiently small sizes.
  • LEDs with a footprint of 0.3 mm 2 or less are used.
  • PCB flexible printed circuit board
  • the catheter device can use any light emitting elements providing the requisite capabilities, but at the present time LEDs are preferred, if only for cost reasons.
  • the light emitting elements preferably each emit light across a volume having the shape of a spherical sector, for example a spherical sector with an angle of 140° at its apex is typical.
  • the light emitting elements of the light source may each be placed adjacent to additional light emitting elements in each of the three regions so that the light from each light emitting element overlaps with the light from the adjacent light emitting elements.
  • the light emitting elements may be arranged in an array having multiple parts including some or all of a first, distal part located at the first region for projecting light forward in the distal direction, a second, central part located at the second region for projecting light outwardly from the longitudinal axis of the distal end of the catheter device, and a third, proximal part located at the third region for projecting light around the point of entry of the catheter device into the body cavity or hollow organ.
  • the third region is outside the expansion and positioning balloon and the second region is at least partly inside, or fully inside the expansion and positioning balloon.
  • the first region may be outside of the expansion and positioning balloon and is preferably at the opposite side of the balloon to the third region.
  • One or more of the three parts of the array of light emitting elements may preferably also project light in other directions.
  • the light projected from the various parts of the array may overlap or at least will form a complete volume of projecting light for extending across the entire inner surface of the wall of the body cavity or hollow organ.
  • the plurality of light emitting elements may be arranged to project light from within the body cavity or hollow organ onto a roughly spherical surface, with no shadows or non-illuminated regions, aside from of course at the opening to the body cavity or hollow organ (e.g. across the cross-section of the urethra where the bladder is treated) where the main body of the catheter will be present and naturally illumination is both not possible and also not required.
  • the first, distal part of the array may be arranged to project light forward in the distal direction and also in a volume encompassing at least a cone or spherical sector centred on the longitudinal axis of the distal end and broadening in diameter in the distal direction.
  • the first part of the array may project light across a larger part of a sphere centred on the longitudinal axis of the distal end, including projecting some light outward normal to the longitudinal axis and optionally backward toward the proximal direction i.e. across a volume with the shape of a sphere with a spherical sector missing.
  • the shadow in the light projected by the first part may be a cone (or spherical sector) centred on the longitudinal axis of the distal end and broadening in diameter in the proximal direction.
  • the second, central part of the array may be arranged to project light outwardly from the longitudinal axis of the distal end, i.e. in directions extending normal to the axis.
  • the second part may be arranged to project light both normal to the axis and also in volumes extending forward and backward along the distal and proximal directions, thereby illuminating a volume of the form of a cylinder or sphere centred on the longitudinal axis of the distal end with conical shadows/non-illuminated regions at either end of the cylinder and centred on the longitudinal axis.
  • the third, proximal part of the array may be arranged to project light in a similar manner to the second part, but from the third region which is closer to the entrance to the hollow organ or body cavity than the second region.
  • the third part may project light in a volume encompassing a cylinder or sphere with two conical shadows/non-illuminated regions at either end of the cylinder and centred on the longitudinal axis. Since it is always necessary with a catheter device for a part of the catheter to pass through the tubular body structure that forms the entrance to the body cavity or hollow organ then, as mentioned above, there will always be a shadow at the opening to the body cavity or hollow organ where illumination is not possible.
  • the array of light emitting elements could include a combined second and third part extending across the second and third regions.
  • an even distribution of light at the required intensity can be achieved if there is separation between the second region and the third region, which then may provide advantages in the structure of the device, for example in relation to space for fluid outlets and/or connection points for the expansion and positioning balloon, as discussed in more detail below.
  • the first part of the array may be at the tip of the distal end of the catheter device, and preferably includes at least one light emitting element at the tip facing in the distal direction, as well as optionally additional light emitting elements located around the tip and facing outward from the direction of the longitudinal axis of the distal end, i.e. normal thereto, and/or facing in directions at an angle between the normal to the longitudinal axis and the distal direction.
  • the second part of the array may be fully within the expansion and positioning balloon and preferably the second region extends across a centre of the expansion and positioning balloon and/or across a location that is at a centre of the body cavity or hollow organ when the device is in use.
  • the second part of the array may include a plurality of light emitting elements spaced around and along the longitudinal axis of the distal end, for example around a cylindrical shape centred on the longitudinal axis.
  • the second part of the array comprises a flexible printed circuit board holding the light emitting elements, the flexible printed circuit board being wrapped in a cylindrical fashion in order to form a generally cylindrical shape holding the light emitting elements of the central part.
  • the light emitting elements on the flexible printed circuit board may be arranged to form a spiral about the cylindrical shape of the central part.
  • the third part of the array may have a similar form to the second part, but would typically have a lesser extent in the direction along the longitudinal axis of the distal end.
  • the third part of the array may hence include a plurality of light emitting elements spaced around and along the longitudinal axis of the distal end, for example around a cylindrical shape centred on the longitudinal axis.
  • a catheter device for treatment of the bladder may have a light source including a third part located at a third region of the distal end, wherein in use the third region sits adjacent and or within the bladder trigone in order to illuminate the trigone walls.
  • Power for each part of the array of light emitting elements may be supplied from the same power source, and preferably a single pair of wires is used to provide power for all of the light emitting elements.
  • the light source may include a circuit for coupling all of the light emitting elements to the power source.
  • the light emitting elements may be simply coupled in series, but preferably both parallel and serial connections are used in the circuit, with parallel connections to keep the voltage low and serial connections to avoid the possibility of one faulty LED consuming all the current. If all of the light emitting elements were identical then this would result in the same light intensity from each of the light emitting elements. However, it may be advantageous to allow for a different intensity of light from different light emitting elements, and in particular for the light emitting elements in the different regions.
  • the circuit for coupling the light emitting elements to the power source may have three power channels (for example LED driver circuits) for the three regions/three parts of the array. This allows for individual tuning of each channel to achieve a required light distribution.
  • the circuit for coupling the light emitting elements to the power source may include an external light emitting element coupled to the light emitting elements of the distal end such that whenever the light emitting elements of the distal end are illuminated then the external light emitting element is also illuminated.
  • This external light emitting element which might be an LED for example, can provide a simple indication of an on-going photodynamic treatment.
  • the expansion and positioning balloon provides for a minimum distance between the light emitting elements and the bladder wall. This hence limits the maximum light dose and ensures a reliable high degree of uniformity of the minimum light dose.
  • the expansion and positioning balloon and optionally the second balloon may act as a passive filter for some or all areas of the balloon and hence limit the light passing through in those areas in order to assist the uniformity of the light projected to the bladder wall.
  • At least one of the expansion and positioning balloon or the second balloon may have a balloon skin comprising a light attenuating medium, such that the attenuation of light passing through the balloon skin varies depending on the level of inflation of the balloon in order to permit regulation of a light dose based on the level of inflation of the balloon.
  • the level of inflation of the balloon can regulate the light dose for the body tissue outside of the balloon.
  • This can provide for automatic control of the light dose in a way that relates to the minimum distance of the body tissue from the light emitting elements, which may be determined by the distance between the light emitting elements and the outer surface of the balloon.
  • the light dose received by an object varies with an inverse square relationship to the distance from the light source to the object. With a small body cavity or hollow organ, for example in the case of a smaller than average bladder, there may be a risk that the distance between the light emitting elements and the body tissue will be to small and an excessive light dose would be received if all of the light was transmitted through the balloon skin.
  • the amount of light that can pass through the balloon at a smaller inflation can be restricted compared to the amount of light at a larger inflation, and this risk is avoided.
  • suitable calibration for the light source and the light attenuating medium it is possible to set the device up to treat a range of bladder sizes whilst delivering a known, constant irradiance level at the bladder wall that is independent of bladder size.
  • the light attenuating medium may be within the material of the balloon or on the surface of the balloon.
  • the light attenuating medium may comprise a pigment or dye, which could be mixed into the material of the balloon skin during manufacture, or coated onto a surface of the balloon skin.
  • the light attenuating medium may comprise particles such as microparticles, nanoparticles or fibres such as microfibers.
  • the light attenuating medium may generate a light attenuating effect by reflection or refraction of light by such particles.
  • particles are arrayed within the balloon skin so that when the balloon is relaxed then the gaps between particles are small, or the particles overlap, but when the balloon is expanded then the gaps between particles increase in size.
  • the light attenuating medium may include plasmonic particles such as gold nanoparticles.
  • plasmonic particles such as gold nanoparticles.
  • SPR surface plasmon resonance
  • the expansion and positioning balloon may be a sheath along and around a part of the distal end when it is in its unexpanded form.
  • this sheath encloses the second region and thus it may fully or partially enclose the second part of the array of light emitting elements.
  • the sheath may sit as a single layer, or it may be at least partially in multiple layers with one or more eversion fold(s) where the sheath turns back on itself.
  • a folded sheath can allow for a larger balloon with less elastic deformation of the balloon during expansion.
  • the balloon may expand both elastically and plastically during use and in this instance the balloon may be larger when deflated after use than prior to deflation.
  • the unexpanded form of the balloon may differ before and after expansion.
  • the balloon may be a single layer sheath prior to expansion, but may at least partially form multiple layers around the distal end when deflated after use.
  • the distal end may have a narrower cross-section at the tip than within the expansion and positioning balloon in order that the double thickness of balloon skin can be held about the tip without the overall cross-section being increased. It will be appreciated that during withdrawal of the distal end from the body cavity or hollow organ then any loose material of the balloon will be slid toward the tip, and allowing a narrower cross-section at the tip means that the folded section of balloon can be accommodated whilst keeping the total cross-section of the distal end within a maximum diameter.
  • the expanded shape of the expansion and positioning balloon is preferably arranged for expansion of the relevant body cavity or hollow organ to produce a smooth wall for the internal surface thereof.
  • the expansion and positioning balloon may for example have a generally spheroidal shape when expanded, including an oblate or prolate spheroid.
  • the expanded shape of the expansion and positioning balloon may have hollows at its outer end where the balloon joins to the distal end of the catheter device.
  • the expansion and positioning balloon may be arranged to bulge outwardly in the distal and/or the proximal direction along the longitudinal axis of the distal end such that the expansion and positioning balloon has a larger extent along the direction of the longitudinal axis when it is expanded than when it is unexpanded.
  • the expansion and positioning balloon may take the form of a spheroid with indentations in one or both ends, for example a shape similar to an apple, which may be a toroidal shape including a horn torus or spindle torus, as well as similar toroids based on ellipses or other shapes rather than on circles.
  • the first region which may include a first part of the array of light emitting elements, may be located outside of the balloon at the distal end of the expansion and positioning balloon.
  • the expansion and positioning balloon preferably has a distal hollow at the distal end when it is expanded, wherein the first region is within the distal hollow.
  • the first region can emit light directly toward the wall of the body orifice or hollow organ beyond the distal end of the catheter device and that the light emitting elements at the first region can be on a tip of the distal end as well as in close proximity to the wall, whilst at the same time the expansion and positioning balloon will act to prevent contact of the tip and/or the light emitting elements with the wall.
  • the expansion and positioning balloon when expanded, preferably extends along the direction of the longitudinal axis of the distal end at least as far as the first region and/or the tip of the distal end. It can be important to avoid contact of the light emitting elements and/or the tip of the distal end with the wall of the body cavity or hollow organ since these parts may be relatively hard and hence could damage the tissue of the wall and also because the light emitting elements may also emit heat, which gives rise to another risk of damage to the tissue of the wall.
  • the size and volume of the expansion and positioning balloon will depend on the body cavity or hollow organ that is of interest.
  • the expansion and positioning balloon may be arranged to expand to a spheroidal or toroidal shape with an expanded diameter and/or height of between 40 mm and 100 mm, for example about 60 mm.
  • This allows for the bladder wall to be expanded without the balloon necessarily filling the entirety of the bladder, so that there is still room for build-up of urine in the bladder and movement of fluid into and around the bladder, for example as a consequence of bodily functions, for cleaning or flushing the bladder and/or for conveying pharmaceutical compositions into the bladder such as a photosensitiser or precursor of a photosensitiser.
  • the second balloon may advantageously be a Foley balloon for expansion at the point of entry of the catheter device into the body cavity or hollow organ in order to prevent flow of fluid through the tubular body structure through which the catheter device is inserted and in order to secure the distal end of the catheter device in place within the body cavity or hollow organ.
  • the third region of the distal end may be partially or fully within the Foley balloon, thereby ensuring that when in use the third region will be located at a known position relative to the point of entry of the catheter device into the body cavity or hollow organ. This means that light projected from light emitting elements at the third part of the array in the third region will reliably illuminate the wall of the body cavity or hollow organ around the point of entry.
  • the Foley balloon of a catheter device for bladder treatment may be similar in form to conventional Foley balloons.
  • the Foley balloon may have a diameter of between 15 mm and 25 mm, for example diameter of approximately 20 mm.
  • the shape or location of the Foley balloon and the expansion and positioning balloon may be such that when both balloons are expanded there is a space or a channel for flow of fluid between the two balloons toward the longitudinal axis of the distal end. In one example this may be achieved by ensuring that the distance between the balloons cannot be bridged by the balloons even when fully expanded.
  • one or both balloons may be provided with a contoured shape or an external element attached to the balloon even when the two balloons are fully expanded and in contact with another then a space or channel remains for flow of fluid between the balloons toward the longitudinal axis of the distal end.
  • the material of the balloon(s) may be any elastic material suitable for medical use and having an appropriate degree of transparency to the wavelengths required for treatment emitted from the light emitting elements.
  • the balloon material is fully elastic and thus after being expanded it will return to its original unexpanded size and shape. Latex, silicone, PVC or rubbers can be used for the material for the balloon.
  • the balloon and the catheter may be made of the same material. Having the catheter and the balloon made from the same material is beneficial as it is then easier to bond them together.
  • the balloon(s) may be formed on a mandrel by dipping and then later bonded to the body of the distal end.
  • the balloon(s) may take the form of a sheath about the body of the distal end when in their unexpanded form. This may be a simple cylindrically tubular sheath, or it may be a more complex shape in order to reflect the intended shape of the balloon after it has been expanded.
  • the expansion and positioning balloon has an unexpanded shape taking the form of a tube with a varying diameter having a central cylindrical section at a first diameter flanked by two sections with decreasing diameter and the two ends at a second diameter, which is smaller than the first diameter. The diameter may decrease linearly in the two sections with decreasing diameter.
  • the distal end of the catheter device is preferably provided with at least one fluid inlet/outlet within the positioning and expansion balloon, and similarly within the Foley balloon when present.
  • the balloon(s) may be expanded by injecting a fluid into the balloon via the catheter device.
  • the fluid may be saline, for example.
  • the fluid may optionally include a light diffusing ingredient, for example a dissolved ingredient or a suspension of particles.
  • a light diffusing ingredient for example a dissolved ingredient or a suspension of particles.
  • the catheter device has a single fluid passage both for supplying fluid and for removing fluid from the (or each) balloon.
  • the body of the distal end is preferably provided with a fluid inlet and a fluid outlet for communication with the inside of the hollow organ or body cavity.
  • This allows for circulation of fluid within the hollow organ or body cavity, outside of the balloon(s), for example for flushing out the bladder, as well as allowing for fluid to be drained from the hollow organ or body cavity or for fluid to be instilled into the hollow organ or body cavity.
  • fluid e.g. saline
  • a liquid e.g. a buffer or saline
  • the liquid will act as a spacer during distension of the organ during expansion of the balloon and can provide a lubricant effect.
  • saline or similar fluid for distension of the organ.
  • the catheter device generally includes an elongate catheter body extending from the distal end to a proximal end of the catheter device.
  • This elongate catheter body may include lumens for transport of fluid to and from the various outlets, and optionally for passage of electrical wires, for example to provide power to the light source.
  • the catheter body may include lumens for passage of fluid and wires embedded in walls of the catheter body. The latter arrangement can allow for a smaller diameter of the catheter body, which reduces patient discomfort in cases where the structure that connects the body cavity or hollow organ to the outside of the body is narrow in diameter, e.g. the urethra in case of the bladder.
  • the catheter body may also carry further wires, for example wires coupled to sensors at the distal end as discussed below.
  • the catheter body may also carry an optical fibre to transmit light from inside to outside of the patient as an indicator that there is illumination at the distal end of the catheter device.
  • the outer diameter of the catheter body may be generally dependent on its use would generally be comparable to similar catheters of the art: for catheters to be used in fairly large organs like the stomach (i.e. inserted into the esophagus and ultimately into the stomach), the catheter may have a larger outer diameter than if inserted through the urethra into the bladder.
  • the outer diameter is preferably small enough to fit within the portion of the body to which it is inserted to (esophagus, urethra) and to house internally contained components and lumens.
  • the catheter body comprises a flexible plastic or polymeric material suitable for medical use in general and catheter bodies in particular.
  • Appropriate materials may include silicones, latex, rubbers, polyurethanes and combinations of these materials.
  • the catheter body may have an antiseptic coat to prevent bacterial infection of the body cavity/hollow organ or other body tissue it comes in contact with, e.g. the urethra, or an analgesic coat, e.g. a coat with lidocaine or similar local anaesthetics.
  • the proximal end of the catheter body may be coupled to one or more external elements of the catheter device, for example a power source, one or more fluid reservoir(s) for inflation of the balloons(s) and/or for instilling fluid into the body orifice or hollow organ, a receptacle for receiving fluids flushed from the body orifice or hollow organ, and/or a controller.
  • the external elements of the catheter device remain outside of the patient's body during use of the device.
  • the device may include one or more fluid reservoir(s) for inflation of the balloons(s), these fluid reservoir(s) advantageously taking the form of syringes or other manually actuatable devices such as an infusion bag for delivery of fluid into the balloon(s). If an infusion bag is used then the fluid flow from the bag into the body can be stopped using a clip/clamp and enabled by removing the clip/clamp. The fluid will run into the bladder by gravitational force. These are typical arrangements for a conventional Foley balloon. As a result, the device can be operated by anyone with the necessary training to use a conventional catheter equipped with a Foley balloon, and in any clinical setting with equipment suitable for purpose.
  • the fluid reservoir for instilling fluid into the body orifice or hollow organ could take the form of a bag supplying the catheter device through a drip type arrangement, or alternatively a syringe could be used. This can provide fluids for flushing the body orifice or hollow organ and/or it might also be used for instillation of the photosensitiser or precursor of a photosensitiser.
  • the catheter device may include a pressure activated device provided at the proximal end of the catheter body in order to provide an indication and/or a release of pressure in the event that the pressure within the expansion and positioning balloon and/or within the second balloon exceeds a threshold level.
  • a pressure activated device provided at the proximal end of the catheter body in order to provide an indication and/or a release of pressure in the event that the pressure within the expansion and positioning balloon and/or within the second balloon exceeds a threshold level.
  • a safety balloon having larger stiffness than the expansion and positioning balloon and/or within the second balloon and connected to the same source of fluid, such that if the expansion and positioning balloon and/or within the second balloon experiences a pressure over a certain threshold then the safety balloon will inflate and provide a visual indication of an overpressure situation.
  • a pressure relief valve may be present, allowing for fluid to be vented from the system when there is an overpressure.
  • a passive system such as a safety balloon or a passive pressure relief valve can provide a reliable way to ensure that a warning or a pressure release can be triggered when the pressure is too high.
  • This type of a passive system allows for the pressure within the body to be monitored in a very simple way without the need for additional sensors or electronics within the distal end of the device, and this can aid in making a ‘disposable’ device that is suitable for single-use.
  • the catheter device may include a pressure sensor, such as a pressure sensor linked with the controller mentioned below, although as noted above this can have the disadvantage of adding extra components within the distal end, and increasing the complexity of the electronics.
  • one of the external elements is a controller including a power source for the device.
  • the controller may include control circuit, such as a microcontroller or microprocessor, for controlling the light source and for providing indications relating to operation of the device.
  • control circuit comprises a timer arranged to provide activation of the light source after a preset time period and/or for a preset time period.
  • control circuit may be arranged to provide pulsed illumination. This can be achieved by providing a function generator within a microprocessor. Pulsed light may be advantageous in ensuring that no unacceptable heating of tissue occurs. In addition, providing intervals in illumination enhances tissue oxygenation and the effect of PDT. If a precursor of a photosensitiser such as 5-ALA or derivatives thereof are used for the PDT, which are converted to protoporphyrins, it allows for the re-accumulation of protoporphyrins and oxygen in surviving cells that can be treated with repeated illuminations. The frequency and length of the pulses can be chosen according to the requirements of the treatment regime and set within the control circuit.
  • the control circuit may be programmable enabling it to be programmed by the user. This enables the length of illumination and the illumination pattern to be adjusted to suit individual treatments. In a preferred embodiment, the control circuit is not programmable by the user and only comprises features to start the device and indicators for the performance of the device as mentioned below.
  • control circuit further comprises a display system for providing indications about the operation of the device.
  • the display may indicate the time elapse and/or time remaining for the PDT.
  • One simple form for the display is a set of indicator lights such as LEDs.
  • control circuit is one or more performance indicator, such as a light or a sound emitter, for informing a user whether the device has operated correctly or whether a fault has occurred.
  • the distal end of the catheter device may preferably include one or more sensor for measuring a parameter relating to the performance of the device, for example the light dose, a temperature and/or a pressure.
  • a temperature at the distal end of the device may be measured in order to obtain an indication of the temperature of the walls of the body cavity or hollow organ.
  • the temperature of the fluid inside or outside of the balloon(s), the temperature of the body of the distal end, or the temperature of a PCB holding the light emitting elements may be measured, with a calculation then being made to relate this to a temperature of the wall of the body cavity or hollow organ, and an alert being provided if the measured temperature indicates a potentially excessive temperature at the wall of the body cavity or hollow organ, for example a temperature over 43° C.
  • a temperature between body temperature of the patient and 43° C. is beneficial since it speeds up the photodynamic therapy. Consequently, it is not required nor beneficial to limit heat generation from the light source to body temperature and below.
  • a pressure sensor may be used to measure the pressure within one or both balloons in order to provide an indication of potential leakage or rupture, which would result in an unexpected change in the pressure.
  • An additional pressure sensor may measure pressure within the bladder fluid outside of the balloon(s) with a differential between the pressure inside a balloon and the pressure outside of the balloon being used to determine if there has been a breach of the balloon.
  • An alert may be provided by the control circuit in the event that the pressure sensor(s) provide readings indicative of a breach of a balloon.
  • the catheter device is designed for a single-use and for disposal after that single use.
  • the device includes one or more features that promote single-use and/or prevent repeat use.
  • the power source may be arranged to provide power that is only sufficient for a single-use, i.e. such that the power source is depleted after the required treatment is complete.
  • the power source may be arranged so as not to be re-charged, and/or the control circuit may lack access to re-charge the power source.
  • the control circuit may be arranged to prevent re-use by means of features of its programming, for example by permitting only a single activation of the light source, and/or it may include a deactivation mechanism that destroys circuitry or software when triggered.
  • the invention also extends to the catheter device of the first aspect or preferred embodiments thereof as discussed above when in a kit form comprising the catheter device and a photosensitiser or precursor thereof for PDT treatment. Suitable photosensitisers and precursors of photosensitisers are discussed below.
  • a resistance meter connected across the balloon wall may provide an additional or alternative way to identify a breach of a balloon. When the balloon wall ruptures then the resistance over the balloon wall will drop.
  • the present invention provides a catheter device for use in the treatment of a body cavity or hollow organ of the body, the catheter device comprising: a distal end portion having a longitudinal axis and being for insertion into the body cavity or hollow organ, the distal end portion including: an expansion and positioning balloon for expanding within the body cavity or hollow organ and thereby distending an outer wall of the body cavity or hollow organ, and a resistance meter for measuring electrical resistance across the balloon wall, whereby an indication of rupture of the balloon can be provided.
  • the resistance meter may be connected to a controller that provides an alert indicating a rupture of the balloon in reaction to a drop in resistance.
  • the invention provides a method comprising use of the catheter device of the first aspect in the photodynamic treatment of a body cavity or hollow organ.
  • the method may include the use of a device having any or all of the preferred features set out above.
  • the method generally includes insertion of the catheter device to an appropriate extent into the body cavity or hollow organ of interest, expanding the body cavity or hollow organ using the expansion and positioning balloon, and irradiating an internal surface of the body cavity or hollow organ with light from the light source.
  • the method includes administration of a photosensitiser or precursor of a photosensitiser to a patient in need of such photodynamic treatment.
  • administration may be a systemic administration, i.e. parenteral administration, e.g. intramuscular or intravenous administration.
  • the method includes local administration to the body cavity or hollow organ, e.g. instillation of a photosensitiser or precursor of a photosensitiser into the body cavity or hollow organ prior to insertion of the catheter device, or whilst the catheter device is inserted, optionally using a lumen of the catheter device to instil the photosensitiser or precursor of a photosensitiser.
  • the photosensitiser or precursor of photosensitiser may be applied to the body cavity or hollow organ by contact of the expandable structure or other parts of the catheter device with the internal surface of the body cavity or hollow organ.
  • Example procedures are set out in more detail below, along with details of suitable photosensitisers or precursors of photosensitisers.
  • the method preferably includes providing a photosensitiser or precursor of a photosensitiser as a composition in soluble form and administration as a dissolved composition, preferably by the catheter to the body cavity or hollow organ.
  • the catheter device may be arranged so that the second balloon is used to retain the distal end in place in the body cavity or hollow organ whilst fluid is instilled into the body cavity or hollow organ via the catheter device in order to administer the photosensitiser or precursor of a photosensitiser.
  • the expansion and positioning balloon may be in its deflated state during this process.
  • the method may include supplying the composition in a sealed package, e.g. a sealed glass vial, along with a solvent to prepare a dissolved composition and the catheter device, which can advantageously be a single use device.
  • a sealed package e.g. a sealed glass vial
  • the dissolved composition may be allowed to remain in the body as appropriate to achieve the required photosensitising effect. If a composition comprising a photosensitiser was instilled into the body cavity or hollow organ via the catheter device, said body cavity or hollow organ may be expanded immediately after instillation using the expansion and positioning balloon, and PDT may be carried out irradiating an internal surface of the body cavity or hollow organ with light from the light source. If a composition comprising a precursor of a photosensitiser was administered parentally or instilled into the body cavity or hollow organ, said precursor first needs to be converted to an active photosensitiser, e.g. to protoporphyrins, before PDT can be carried out.
  • an active photosensitiser e.g. to protoporphyrins
  • the incubation time is generally 5 min to up to 12 hours, such as 10 min to 2 hours or 30 min to 1 hour and thereafter PDT may be carried out irradiating an internal surface of the body cavity or hollow organ with light from the light source.
  • the invention provides a method of photodynamic treatment of a body cavity or hollow organ, the method comprising: administering a photosensitiser or precursor of a photosensitiser to a patient in need of said treatment, inserting a device according to the first aspect into the body cavity or hollow organ of interest, expanding the body cavity or hollow organ using the expansion and positioning balloon, and irradiating an internal surface of the body cavity or hollow organ with light from the light source.
  • the method may include use of a device having any or all of the preferred features set out above.
  • the method may include using the second balloon to retain the device in place and seal the body cavity or hollow organ whilst fluid is instilled into the body cavity or hollow organ, for example to flush out the body cavity or hollow organ before or after treatment, and/or to instil a photosensitising composition or a precursor of a photosensitiser.
  • Methods relating to use of the catheter device in PDT provide a new medical use for the photosensitiser or precursor thereof, and thus another aspect of the invention provides a composition comprising 5-ALA, a derivative of 5-ALA or a pharmaceutically acceptable salt thereof for use in a method for photodynamic therapy, the method comprising: administration of the composition to a patient in need of such a photodynamic therapy, inserting a device according to the first aspect into a body cavity or hollow organ of interest, expanding the body cavity or hollow organ using the expansion and positioning balloon, and irradiating an internal surface of the body cavity or hollow organ with light from the light source.
  • FIG. 1 shows a schematic overview of a catheter device including all parts to be provided to the user in preferably sterile packaging
  • FIG. 2 shows a similar schematic with the catheter device in use, having its distal end inserted within and being provided with additional consumables;
  • FIG. 3 shows a close-up view of the distal end of the catheter device in use, again in schematic view;
  • FIG. 4 and FIG. 5 show a perspective view and a side view of the distal end of a catheter device with a partial cutaway of some elements so that the construction and layout of the device can more clearly be seen.
  • the catheter device consists of a distal end 10 , a catheter body 12 extending from the distal end 10 to a proximal end 14 , and various external elements at the proximal end 14 .
  • the distal end 10 and a portion of the catheter body 12 are within a body cavity or hollow organ of a patient's body with the remainder of the catheter body 12 and the proximal end 14 with its external elements being at the outside of the patient's body.
  • the divide between the parts that are internal to the patient's body and the parts that are external to the patient's body is shown by the vertical line 16 .
  • the catheter device is adapted for use with the bladder and thus, by way of example, the geometry and size of the device relates to the bladder. It will however be appreciated that adaptations could easily be made to this device to arrive at a catheter device for treatment of other body cavities or hollow organs.
  • the catheter body 12 in this example is a multiple lumen catheter that is both flexible and is preferably disposable.
  • the diameter of the catheter may be any suitable size for the intended use and hence here the catheter is sized for insertion to the bladder.
  • the diameter may be 8 mm or 9 mm, for example, but preferably it is lower and a preferred embodiment uses a 20 French catheter, i.e. diameter of 6.9 mm.
  • the catheter and the wiring associated with providing power and control signals is flexible allowing for a bend radius as low as 25 mm.
  • the distal end 10 which is preferably disposable, includes an expansion and positioning balloon 18 and a Foley balloon 20 .
  • the expansion and positioning balloon 18 is arranged to expand to a diameter of at least 58 mm with a volume of 99 mL.
  • the Foley balloon 20 is arranged to expand to a diameter of 20 mm and have a volume of 3 mL.
  • the balloons 18 , 20 may be made of latex formed on a mandrel. Alternative materials may be used, such as thermoplastic nylon materials.
  • the material of the balloon skin includes a light attenuating medium such as a pigment or dye in order to allow for the degree of expansion of the balloon to vary the light dose as discussed above.
  • the use of a light attenuating medium in the balloon skin can apply to the expansion and positioning balloon 18 and to the Foley balloon 20 .
  • FIG. 1 shows a very schematic indication of the balloons 18 , 20 in their unexpanded shape, with a dashed line showing the expanded shape.
  • FIGS. 2 and 3 show the balloons 18 , 20 expanded with an indication of the position of the bladder wall 73 and, in FIG. 3 , the trigone 74 .
  • the distal end 10 also includes a light source for providing the necessary illumination for the required PDT.
  • This light source comprises an array of light emitting elements, in this example LEDs, provided in three parts that are at three regions of the distal end.
  • a central part 22 of the array of light emitting elements is at a second region of the distal end, this second region being within the expansion and positioning balloon 18 .
  • a distal part 24 of the array of light emitting elements is at a first region of the distal end 10 , this first region being at a tip of the distal end and preferably being outside of the expansion and positioning balloon 18 , as shown in more detail in FIG. 3 as well as in FIGS. 4 and 5 , discussed below.
  • a proximal part 26 of the array of light emitting elements is at a third region of the distal end 10 , which in this example is within the Foley balloon 20 , and which is at a location closer to the entry point of the catheter into the bladder than the second region.
  • Each of the three parts 22 , 24 , 26 of the array of light emitting elements includes multiple LEDs.
  • the LEDs are selected for the production of red light, e.g. red light at a wavelength of 635 nm.
  • a possible arrangement for the LEDs is described below with reference to FIGS. 4 and 5 .
  • the arrangement of the LEDs for any required application can be determined by modelling of the light produced in order to achieve the required effect, which would typically be even illumination of a bladder target shape defined as nominally spherical of given diameter with a given target fluence rate and/or light dose for the required treatment.
  • the modelling might provide even illumination of a bladder target shape defined as nominally spherical of diameter approximately 70 mm and a target fluence rate in the range 15-25 mW/cm 2 .
  • the distal end 10 additionally includes flow passages for flow of fluid into and out of the two balloons 18 , 20 and for flow of fluid into and out of the bladder.
  • a single flow passage is provided for communication with each balloon, and hence fluid injected into the balloons and fluid extracted from the balloons passes in opposite directions through the same passage and in opposite directions through the same lumen within the catheter body 12 .
  • the catheter body 12 would hence include two lumens for supply of and for discharge of fluid from the two balloons 18 , 20 , a first lumen connecting to a passage 28 within the expansion and positioning balloon 18 and second lumen connecting to a passage 30 within the Foley balloon 20 .
  • the passages 28 , 30 can be seen in FIG. 3 as well as in FIGS. 4 and 5 .
  • inlet 32 and an outlet 34 for fluid communication with the internal volume of the bladder 73 in order to allow for flushing of the bladder during PDT (for example to remove blood and the like that might impact on the effectiveness of the illumination), to drain urine and also potentially to allow for instillation (and draining) of the photosensitiser or precursor of the photosensitiser.
  • the inlet 32 may also be used for injecting saline to act as lubricant fluid during expansion of the balloons.
  • the inlet 32 in this example is close to the tip of the distal end 10 , lying close to the distal part 24 of the array of light emitting elements.
  • Flush fluids can circulate from the top of the expansion and positioning balloon 18 into the bladder 73 , around the balloon 18 and then toward the outlet 34 , which is located between the expansion and positioning balloon 18 and the Foley balloon 20 as shown most clearly in FIG. 3 .
  • the catheter body 12 would therefore require a further two lumens for separate supply of fluid to and discharge of fluid from the bladder. This embodiment hence requires four lumens in total for movement of fluids along the catheter body 12 .
  • the catheter body is provided with a splitter 36 at its proximal end, in this example a four-way splitter 36 .
  • a splitter 36 at its proximal end, in this example a four-way splitter 36 .
  • a first conduit 38 for introducing flush fluids extends toward a flush fluid connector 40 , which in use can be connected to a reservoir for supply of flush fluids, for example a drip type arrangement 42 , shown in FIG. 2 .
  • a second conduit 44 for injection of fluid into the Foley balloon 20 extends towards a Foley balloon fluid supply connector 46 , which in use can be connected to a reservoir for supply of a fluid, for example saline, to the Foley balloon 20 .
  • the reservoir for supplying saline to the Foley balloon 20 may be a manually operated syringe 48 , for example (shown in FIG. 2 ).
  • the use of a manual syringe is preferred since this allows the catheter device to be operated in accordance with usual procedures for known catheters and without the need for special training or special equipment.
  • a third conduit 50 extends towards a fluid discharge connector 52 and is for discharge of (flush) fluids from the bladder.
  • the fluid discharge connector 52 may be attached to an appropriate collection reservoir such as a bag 54 as shown in FIG. 2 .
  • the final, fourth, conduit 56 extends towards a further splitter, in this example a two way splitter 58 , which acts to separate out a flow line 60 for supplying fluid to the expansion and positioning balloon 18 from a communications conduit 62 that carries wires for control signals and supply of power.
  • a flow line 60 for supplying fluid to the expansion and positioning balloon 18 from a communications conduit 62 that carries wires for control signals and supply of power.
  • the fluid for the expansion and positioning balloon 18 travels along the same conduit 56 as the wires since the main electrical connections at the distal end are found in close proximity to the flow passage 28 that opens into the expansion and positioning balloon 18 .
  • the flow line 60 extends towards a connector 64 that, in use, is connected to a reservoir for supply of a fluid, such as saline, to the expansion and positioning balloon 18 .
  • this reservoir is advantageously a manually operated syringe 66 .
  • the volume of the syringe 66 for the expansion and positioning balloon 18 is somewhat larger than the volume of the syringe 48 for the Foley balloon 20 .
  • the Foley balloon syringe 48 might have a volume of 5 mL and the expansion and positioning balloon syringe 66 might have a volume of 100 mL.
  • the communications conduit 62 connects to a controller 68 , which in this example also includes a battery as a power source for the light source.
  • the controller 68 includes a control button 70 as well as LED indicators 72 providing a means to display feedback to the user. Since the device is designed and intended for single use then the control button 70 may have only a small number of functions, in particular it may start the light illumination, i.e. PDT treatment and it may also be able to pause or stop the light illumination for example in the event of an adverse reaction by the patient.
  • the LED indicators 72 may illuminate to provide an indication of on-going illumination, the amount of time elapsed in the treatment, or the amount of time remaining, and they may also be used to indicate faults or alerts and provide additional information. For example the LEDs may be used for indicating battery condition, showing if the device is in a pulsed mode of illumination, and indicating faults or alerts such as an excessive temperature, a potentially ruptured balloon, and so on.
  • the distal end 10 may include one or more temperature or pressure sensor at an appropriate location.
  • the temperature of the fluid inside or outside of the balloon(s) 18 , 20 , the temperature of the body of the distal end, or the temperature of a PCB holding the light emitting elements may be measured, with a calculation then being made to relate this to a temperature of the wall of the bladder, and an alert being provided if the measured temperature indicates a potentially excessive temperature at the wall of the body cavity or hollow organ, for example a temperature over 43° C.
  • a pressure sensor may be used to measure the pressure within one or both balloons in order to provide an indication of potential leakage or rupture, which would result in an unexpected change in the pressure.
  • An additional pressure sensor may measure pressure within the bladder fluid outside of the balloon(s) with a differential between the pressure inside a balloon and the pressure outside of the balloon being used to determine if there has been a breach of the balloon.
  • An alert may be provided by the control circuit in the event that the pressure sensor(s) provide readings indicative of a breach of a balloon.
  • Wiring from the controller 68 passes along the communications conduit 62 and then along the fourth conduit 56 into the catheter body 12 , where the wires are held either within one or more lumens or are embedded in the walls of the catheter body 12 and re-emerge at the distal end 10 , where they are electrically connected to the light source and the temperature/pressure sensors.
  • the catheter device in FIG. 1 is advantageously provided for single-use and hence is disposable.
  • FIG. 3 shows a close-up of the distal end 10 of the catheter device with the balloons 18 , 20 , expanded and the distal end 10 in position within the bladder 73 .
  • the main features of the distal end 10 have already been described above. It will be recalled that a gap between the Foley balloon 20 and the expansion and positioning balloon 18 allows for fluid to flow easily into the outlet 34 for the (flush) fluids as shown by the arrows. This also avoids any obstruction of the bladder ureteral opening 72 by the balloons 18 , 20 .
  • the Foley balloon 20 sits within the bladder trigone 74 , which means that the proximal part 26 of the light source, which is located within the Foley balloon 20 , can effectively provide illumination within and around the bladder trigone 74 .
  • the central part 22 of the array of light emitting elements which is in the expansion and positioning balloon 18 , sits generally centrally within the bladder and is well-positioned to illuminate the majority of the bladder wall 73 .
  • the proximal part 26 of the array of light emitting elements addresses a shadow that would arise in the proximal direction along the distal end 10 from the central part 22 .
  • the distal part 24 of the array of light emitting elements which is located at the tip of the distal end 10 eliminates any shadow that would arise in the distal direction along the distal end 10 from the central part 22 .
  • the central part 22 uses higher intensity light whereas the proximal and distal parts use lower intensity light, the required difference in intensity can be achieved by the use of LEDs of different power/light intensity.
  • FIG. 3 also shows more detail of the shape of the balloons when expanded.
  • the expansion and positioning balloon 18 forms a toroidal type shape with a generally spherical outer profile and hollows at the proximal and distal end similar to the hollows found in a horn torus or spindle torus.
  • the Foley balloon 20 can also take a similar toroidal type shape, although it preferably is more spherical.
  • FIGS. 4 and 5 show the distal end 10 , with the balloons in their unexpanded form, in a more accurate and less schematic example.
  • the same basic features are present.
  • the distal part 24 of the array of light emitting elements sits at the tip of the distal end 10 just beyond an inlet 32 for flush fluids.
  • the expansion and positioning balloon 18 is joined to the body of the distal end 10 below the inlet 32 for flush fluids and at either side of a central part 22 of the light source.
  • a flow passage 28 for injection of fluid into the expansion positioning balloon 18 is located within the expansion and positioning balloon 18 . Below the expansion positioning balloon 18 (i.e.
  • the outlet 34 for (flush) fluids being discharged from the bladder is positioned between the expansion and positioning balloon 18 and the Foley balloon 20 .
  • the Foley balloon is attached to the body of the distal end 10 on either side of a proximal part 26 of the array of light emitting elements and a flow passage 30 for injection of fluid into the Foley balloon 20 is within the Foley balloon 20 .
  • the catheter body 12 extends from the proximal part of the distal end toward the proximal part of the device and the external elements (not shown) which would be as described in relation to FIG. 1 and FIG. 2 above.
  • the distal part 24 of the array of light emitting elements includes LEDs in a dome like structure 80 for directing light in the distal direction along the longitudinal axis of the distal end 10 and also illuminates a region around the distal direction in a spherical segment.
  • the central part 22 of the array of light emitting elements is made up of a flexible PCB wrapped to form a cylinder and having four rings each made of four LEDs 76 , thereby directing light in all directions around and away from the longitudinal axis of the distal end 10 .
  • the proximal part 26 of the array of light emitting elements is made of LEDs 78 placed about the circumference of the body of the distal end 10 within the Foley balloon 20 .
  • the LEDs within the dome like structure 80 in the distal part of the array of light emitting elements and the LEDs 78 in the proximal part of the array of light emitting elements will be closer to the tissue of the bladder wall than the LEDs 76 in the central part 22 . Therefore, the LEDs 76 will be of higher power/higher intensity than the LEDs in the proximal part 26 and the distal part 24 .
  • the LEDs are in contact with liquids when the device is in use then they should be sealed against ingress of liquid, as should the associated electrical wiring/circuitry. This can be done via a layer of resin or plastic.
  • FIG. 4 and FIG. 5 also show more effectively a preferred form for the balloons 18 , 20 in their unexpanded shape.
  • the shape can be formed out of a suitable elastic material, such as latex, by means of a mandrel.
  • a suitable elastic material such as latex
  • the balloon is bonded to the main body of the distal end 10 at two outer tubular sections of lesser diameter.
  • a central tubular section of greater diameter than the outer sections sits across the centre of the balloon, and in this case over the central part or proximal part of the light source.
  • Two sections of varying diameter join the tubular sections.
  • a balloon of this form when unexpanded will take the required toroidal type shape when it is filled with fluid and expanded.
  • the catheter device When in use the catheter device is inserted into the body in conventional fashion for a catheter. Before inserting the catheter device, it may be coated with an analgesic, e.g. lidocaine. There is no general anaesthesia required, but the physician may decide to use a local anaesthetic. The user may be able to judge when the distal end 10 has reached the bladder (or other target body cavity or hollow organ) based on their experience and training, or alternatively in difficult cases all for harder to reach body cavities or organs some form of guidance may be used, such as ultrasound imaging.
  • an analgesic e.g. lidocaine.
  • an analgesic e.g. lidocaine
  • the user may be able to judge when the distal end 10 has reached the bladder (or other target body cavity or hollow organ) based on their experience and training, or alternatively in difficult cases all for harder to reach body cavities or organs some form of guidance may be used, such as ultrasound imaging.
  • the Foley balloon 20 When the distal end is in place the Foley balloon 20 is inflated by means of the Foley balloon syringe 46 . This ensures that the distal end cannot leave the bladder or other target organ, and it also facilitates correct location of the remaining parts of the distal end inside of the bladder.
  • the Foley balloon 20 After inflation of the Foley balloon 20 it may be required to flush the bladder or to instil a photosensitising drug or precursor thereof. Saline may be injected to act as a lubricant during the inflation of the expansion and positioning balloon 18 .
  • the expansion and positioning balloon 18 is inflated by injecting fluid from the expansion and positioning balloon syringe 64 . After the required incubation time has passed, if applicable, the patient with then be ready for treatment.
  • Illumination via the three parts 22 , 24 , 26 of the array of light emitting elements can be started by means of the controller 68 , typically by pressing the button 70 .
  • the controller 68 will ensure that the light source emits light for the required period of time, to provide a required light dose, whilst also continually checking for any fault or failure, including monitoring temperature and pressure as discussed above.
  • the controller will indicate that the treatment has been completed and the catheter device may be removed.
  • To remove the device fluid is removed from the expansion and positioning balloon 18 and from the Foley balloon 20 using the respective syringes and the catheter device can be extracted from the body in a conventional fashion.
  • the preferred PDT procedure starts with the administration of the photosensitiser or precursor of photosensitiser.
  • the mode of administration is dependent on which photosensitiser or precursor is used and has been described earlier.
  • administration can be done systemically, i.e. parenterally (infusion, injection), enterally (oral or rectal administration) or topically to the body cavity or hollow organ of interest.
  • Photofrin for instance, is preferably intravenously administered while ALA and ALA-esters are preferably topically or enterally administered, e.g. instilled as a solution into the body cavity/hollow organ (e.g. to the bladder), applied topically to the inner surface of the body cavity/hollow organ (e.g. to the vagina), orally ingested (e.g. stomach, intestines) or rectally administered (intestines).
  • Photosensitisers or precursors of photosensitisers are formulated with compatible excipients that are known in the art as described for instance in WO 96/28412, WO 99/53962, WO 2009/074811, WO 2010/072419, WO 2010/142456, WO 2010/142457, WO 2011/161220, WO 2012/004399 and WO 2014/020164.
  • the photosensitiser or precursor of photosensitiser can be formulated as a solution, preferably aqueous solution.
  • the photosensitiser or precursor of photosensitiser can be formulated as a solid for oral administration, e.g.
  • the photosensitiser or precursor of photosensitiser can be formulated as a semi-solid for oral or rectal administration, e.g. a gel, emulsion, foam or ointment.
  • the photosensitiser or precursor of photosensitiser can be formulated as a liquid for oral administration, e.g. a solution, suspension, syrup or for rectal administration, e.g. an enema.
  • the photosensitiser or precursor of photosensitiser can be formulated as a liquid, e.g.
  • a solution such as an aqueous and/or alcoholic solution or suspension, as a semi-solid, e.g. a cream, emulsion, lotion, ointment, gel, foam and paste or as a solid, e.g. a transdermal patch.
  • the photosensitiser or precursor of a photosensitiser is instilled into the body cavity or hollow organ in the form of a dissolved composition, e.g. dissolved in an aqueous solution such as a buffer.
  • the expansion and positioning balloon may be coated with the photosensitiser or precursor of photosensitiser, preferably in the form of a dry deposit or film, such as described in WO 2012/004399.
  • any known photosensitisers or precursors thereof can be used in a method of PDT wherein the devices proposed herein are used.
  • Typical such photosensitisers include dyes like hypericin and PVP hypericin, psoralens, porphyrins such as hematoporphyrins, protoporphyrins, uroporphyrins, coproporphyrins, benzoporphyrins or deuteroporphyrins, in particular Photofrin® (profimer sodium), photosan III or verteporfin; chlorins, including bacteriochlorins and isochlorins such as chlorine e6, talaporfin or temoporfin and phthalocyanines such as aluminium- and silicon phthalocyanines.
  • Typical such precursors of photosensitisers include 5-aminolevulinic acid (5-ALA) and certain derivatives thereof, e.g. 5-ALA esters, preferably derivatives or pharmaceutically acceptable salts thereof disclosed in WO 96/28412, WO 02/10120, WO 2005/092838, WO 2009/077960 and WO 2014/020164, all of which are incorporated by reference.
  • 5-ALA 5-aminolevulinic acid
  • 5-ALA esters preferably derivatives or pharmaceutically acceptable salts thereof disclosed in WO 96/28412, WO 02/10120, WO 2005/092838, WO 2009/077960 and WO 2014/020164, all of which are incorporated by reference.
  • 5-ALA denotes 5-aminolevulinic acid, i.e. 5-amino-4-oxo-pentanoic acid.
  • precursor of 5-ALA denotes compounds which are converted metabolically to 5-ALA and thus are essentially equivalent thereto.
  • precursor of 5-ALA covers biological precursors for protoporphyrin in the metabolic pathway for haem biosynthesis.
  • derivative of 5-ALA denotes chemically modified 5-ALA, i.e. 5-ALA having undergone a chemical derivation such as substitution of a chemical group or addition of a further chemical group to modify or change any of its physico-chemical properties such as solubility or lipophilicity. Chemical derivation is preferably carried out at the carboxy group of 5-ALA, at the amino group of 5-ALA or at the keto group of 5-ALA, more preferably at the carboxy group of 5-ALA.
  • Preferred derivatives are 5-ALA esters.
  • pharmaceutically acceptable salt denotes a salt fulfils the requirements related to for instance safety, bioavailability and tolerability (see for instance P. H. Stahl et al. (eds.) Handbook of Pharmaceutical Salts, Publisher Helvetica Chimica Acta, Zurich, 2002)
  • Preferred derivatives of 5-ALA are esters of 5-ALA. Such compounds are generally known and described in the literature see, for example, WO 96/28412, WO 02/10120, WO 03/041673, WO 2009/077960 and WO 2014/020164 the contents of which are incorporated herein by reference.
  • Esters resulting from a reaction of 5-ALA with unsubstituted or substituted alkanols i.e. alkyl esters and substituted alkyl esters, and pharmaceutically acceptable salts thereof, are especially preferred derivatives of 5-ALA for use in the preferred embodiments.
  • 5-ALA esters and pharmaceutically acceptable salts thereof for use in the preferred embodiments may be prepared by any conventional procedure available in the art, e.g. as described in WO 96/28412, WO 02/10120, WO 03/041673, WO 2009/077960 and WO 2014/020164 and in N. Fotinos et al., Photochemistry and Photobiology 2006, 82, 994-1015 and the cited literature references therein.
  • the 5-ALA esters may be in the form of a free amine, e.g. —NH 2 , —NHR 2 or —NR 2 R 2 or preferably in the form of a pharmaceutically acceptable salt.
  • Such salts preferably are acid addition salts with pharmaceutically acceptable organic or inorganic acids.
  • Suitable acids include, for example, hydrochloric, nitric, hydrobromic, phosphoric, sulphuric, sulfonic and sulfonic acid derivatives, the salts of ALA-esters and the latter acids are described in WO 2005/092838, the entire contents of which are incorporated herein by reference.
  • a preferred acid is hydrochloride acid, HCl.
  • Further preferred acids are sulfonic acid and sulfonic acid derivatives. Procedures for salt formation are conventional in the art and are for instance described in WO 2005/092838.
  • one preferred photosensitiser is PVP hypericin and preferred precursors of a photosensitiser are 5-ALA, 5-ALA esters or pharmaceutically acceptable salts thereof.
  • Preferred 5-ALA esters are C 1 -C 6 -alkyl substituted 5-ALA esters, such as methyl, ethyl, propyl, butyl, pentyl and hexyl 5-ALA ester, most preferably hexyl 5-ALA ester, and the 5-ALA esters disclosed in WO 2014/020164.
  • a pharmaceutically acceptable salt of the hexyl ester of 5-ALA e.g. hexyl 5-ALA ester hydrochloride.
  • concentration of the photosensitisers or precursors of photosensitisers for use in PDT methods wherein the catheter devices of the invention are used depends upon the nature of the photosensitiser or precursor of photosensitiser, the nature of the composition, the mode of administration, the organ and condition to be treated, and the subject to which it is administered and may be varied or adjusted according to choice.
  • the hexyl 5-ALA ester may be instilled into the bladder as a 8 mM solution of the hydrochloride salt in an aqueous buffer (2 mg/ml; 0.2% by weight) or PVP hypericin may be instilled into the bladder in a total amount of 0.25 mg hypericin bound to 25 mg PVP, reconstituted in 50 ml physiological sodium chloride solution (A. Kubin et al., Photochem Photobiol 2008, 84(6), 1560-1563).
  • photosensitisers first have to be intracellularly converted to photosensitisers, e.g. ALA and ALA-esters to protoporphyrins, such as protoporphyrin IX (PpIX)
  • PpIX protoporphyrin IX
  • the incubation time is generally 5 min to up to 12 hours, such as 10 min to 2 hours or 30 min to 1 hour.
  • the catheter device may be inserted into the body cavity/hollow organ and a lumen therein may be used to instil/administer the photosensitiser or precursor of a photosensitiser to the body cavity/hollow organ.
  • the catheter device may preferably be kept in place, i.e. inside the body cavity/hollow organ. Alternatively, it is withdrawn.
  • the body cavity/hollow organ is distended by means of the expandable structure and the now smooth internal surface of the body cavity/hollow organ is irradiated with light.
  • a separate catheter or other delivery means is used to instil the photosensitiser or precursor to the body cavity or hollow organ.
  • the body cavity/hollow organ Prior to PDT, it may be necessary and/or advantageously to empty the body cavity/hollow organ, e.g. to empty the intestines by help of a bowel cleansing procedure, the bladder by draining urine or the stomach by fasting.
  • body fluids such as urine or gastric acid may be drained from the body cavity/hollow organ by means of the drainage lumen which is an integral part of the catheter device, e.g. the via the outlet 34 and the conduit 50 towards a fluid discharge connector 52 which may be attached to an appropriate collection reservoir such as a bag 54 (as shown in FIG. 2 ).
  • a flush fluid e.g. saline by means of an instillation lumen which is an integral part of the catheter device, e.g. via an inlet 32 and a conduit 38 for introducing flush fluids which extends toward a flush fluid connector 40 , which in use can be connected to a reservoir for supply of flush fluids, for example a drip type arrangement 42 (as shown in FIG. 2 ).
  • the abnormalities, disorders and diseases which may be treated with photodynamic treatment using the proposed catheter devices include any malignant, pre-malignant and benign abnormalities or disorders on the internal surface of a body cavity or hollow organ which are responsive to photodynamic treatment.
  • treatment encompasses curative as well as prophylactic treatment or therapy.
  • cells which are metabolically active are responsive to photodynamic treatment with a photosensitiser or precursor of a photosensitiser.
  • metabolically active cells are cells that undergo an abnormal growth pattern such as increased number of cells/increased cell proliferation (hyperplasia), wherein the cells of a hyperplastic growth remain subject to normal regulatory control mechanisms; abnormal maturation and differentiation of cells (dysplasia); and abnormal proliferation of cells (neoplasia), wherein genetically abnormal cells proliferate in a non-physiological manner which is unresponsive to normal stimuli.
  • Other examples of metabolically active cells are infected or inflamed cells.
  • the proposed catheter devices may be used in photodynamic treatment of neoplasms and tumours (benign, pre-malignant and malignant) on internal surfaces of body cavities and hollow organs.
  • neoplasms and tumours benign, pre-malignant and malignant
  • Examples of such neoplasms and tumours on internal surfaces of body cavities and hollow organs are neoplasms in the vagina, bladder, the colon, the stomach and the gallbladder.
  • the proposed catheter devices may be used in photodynamic treatment of abnormalities, disorders or diseases associated with viral, bacterial and fungal infections of internal surfaces of body cavities and hollow organs such as vaginal or cervical intraepithelial neoplasia (associated with the human papilloma virus), stomach cancer (associated with the bacterium Helicobacter pylori ) and pseudomembranous colitis (associated with the bacterium Clostridium difficile ).
  • the proposed catheter devices may be used in photodynamic treatment of abnormalities, disorders or diseases associated with inflamed cells.
  • Inflammation is usually a protective attempt by the organism to remove the injurious stimuli and to initiate the healing process and thus often associated with an infection.
  • Examples are inflammatory colitis (e.g. inflammatory bowel disease, ulcerative colitis and Crohn's disease)
  • the internal surfaces which may be treated by photodynamic treatment wherein the proposed catheter devices may be used are the internal surfaces of body cavities and hollow organs that comprise rugae, preferably the bladder, the gallbladder, the intestines, the stomach, and the vagina, most preferably the bladder.
  • the catheter device of the invention is for photodynamic treatment of bladder cancer, preferably superficial, non-muscle invasive bladder cancer such as papillary lesions and carcinoma in situ.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Radiation-Therapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
US16/063,203 2015-12-18 2016-12-16 Device for photodynamic treatment Abandoned US20180369603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522398.5A GB201522398D0 (en) 2015-12-18 2015-12-18 Device for photodynamic therapy
GB1522398.5 2015-12-18
PCT/EP2016/081425 WO2017103105A1 (en) 2015-12-18 2016-12-16 Device for photodynamic treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/081425 A-371-Of-International WO2017103105A1 (en) 2015-12-18 2016-12-16 Device for photodynamic treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/875,391 Continuation US11565123B2 (en) 2015-12-18 2020-05-15 Device for photodynamic treatment

Publications (1)

Publication Number Publication Date
US20180369603A1 true US20180369603A1 (en) 2018-12-27

Family

ID=55311234

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/063,203 Abandoned US20180369603A1 (en) 2015-12-18 2016-12-16 Device for photodynamic treatment
US16/875,391 Active 2037-02-12 US11565123B2 (en) 2015-12-18 2020-05-15 Device for photodynamic treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/875,391 Active 2037-02-12 US11565123B2 (en) 2015-12-18 2020-05-15 Device for photodynamic treatment

Country Status (14)

Country Link
US (2) US20180369603A1 (zh)
EP (1) EP3389778B1 (zh)
JP (1) JP6860571B2 (zh)
KR (1) KR102666387B1 (zh)
CN (1) CN108778413B (zh)
AU (1) AU2016369404B2 (zh)
BR (1) BR112018012182B1 (zh)
CA (1) CA3008555C (zh)
DK (1) DK3389778T3 (zh)
ES (1) ES2926984T3 (zh)
GB (1) GB201522398D0 (zh)
PL (1) PL3389778T3 (zh)
RU (1) RU2736406C2 (zh)
WO (1) WO2017103105A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021160751A1 (de) * 2020-02-14 2021-08-19 Albert-Ludwigs-Universität Freiburg Katheter mit antimikrobieller wirkung zur verhinderung der adhäsion
WO2021216605A1 (en) * 2020-04-20 2021-10-28 Cern Corp Vaginal light therapy devices and methods for using them
WO2023151768A1 (de) * 2022-02-09 2023-08-17 Richard Wolf Gmbh Bestrahlungsvorrichtung für die photodynamische therapie
TWI812839B (zh) * 2019-02-25 2023-08-21 日商大塚電子股份有限公司 光動力治療裝置及光動力治療裝置用卡匣盒

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102067583B1 (ko) 2011-12-09 2020-01-17 메타벤션, 인크. 간 시스템의 치료적 신경조절
US10524859B2 (en) 2016-06-07 2020-01-07 Metavention, Inc. Therapeutic tissue modulation devices and methods
WO2018234509A1 (en) * 2017-06-21 2018-12-27 Photocure Asa PROCESS FOR PREPARING A LIQUID PHARMACEUTICAL COMPOSITION AND DEVICE FOR USE IN SUCH A METHOD
EP3710096A1 (en) 2017-11-17 2020-09-23 Convergascent LLC Devices and systems for intraluminal local drug delivery
WO2020037032A1 (en) * 2018-08-17 2020-02-20 St. Jude Medical, Cardiology Division, Inc. Optical balloon catheters and methods for mapping and ablation
KR20200039066A (ko) 2018-10-04 2020-04-16 재단법인 아산사회복지재단 광역학 치료 장치
US20220117716A1 (en) * 2018-12-24 2022-04-21 Innoventions Ltd. Intravesicular device for controlling urinary incontinence
US20200230378A1 (en) * 2019-01-22 2020-07-23 Olympus Corporation Balloon catheter system and method for optical tumor treatment
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
KR102273928B1 (ko) 2019-05-15 2021-07-14 연세대학교 산학협력단 집속초음파 유도에 의해 광투과 깊이를 확보하는 광 조사 장치 및 초음파의 출력을 피드백 제어하여 광을 조사하는 방법
CN110339489B (zh) * 2019-08-09 2020-07-21 尚华 一种新型的血管光纤导丝
CN115052583A (zh) * 2020-01-27 2022-09-13 伊索拉治疗公司 管腔内局部药物递送的组织给药
CN115607844A (zh) * 2020-03-26 2023-01-17 苏州科技城医院 一种基于蓝光led的胃腔光疗杀菌装置及方法
WO2021199976A1 (ja) * 2020-03-30 2021-10-07 テルモ株式会社 治療装置および治療方法
CN112402807B (zh) * 2020-11-18 2021-11-23 中国人民解放军总医院 一种用于人体腔道及空腔器官内的光动力治疗器械
CN112386810B (zh) * 2021-01-19 2021-04-27 武汉亚格光电技术股份有限公司 冷却式内腔治疗用光动力治疗头
RU2767264C1 (ru) * 2021-06-24 2022-03-17 Общество с ограниченной ответственностью "БИОСПЕК" Способ внутрипротоковой фототераностики холангиоцеллюлярного рака
EP4223365A1 (en) * 2022-02-08 2023-08-09 Uvisa Health ApS A device for transmitting light within a body cavity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496271A (en) * 1990-09-14 1996-03-05 American Medical Systems, Inc. Combined hyperthermia and dilation catheter
WO2015006309A1 (en) * 2013-07-10 2015-01-15 Christoph Scharf Devices and methods for delivery of therapeutic energy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5415654A (en) * 1993-10-05 1995-05-16 S.L.T. Japan Co., Ltd. Laser balloon catheter apparatus
CA2215069C (en) 1995-03-10 2006-09-12 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6013053A (en) * 1996-05-17 2000-01-11 Qlt Photo Therapeutics Inc. Balloon catheter for photodynamic therapy
US6146409A (en) * 1996-05-20 2000-11-14 Bergein F. Overholt Therapeutic methods and devices for irradiating columnar environments
JP2001510365A (ja) * 1997-02-04 2001-07-31 クック ウロロジカル インク． 恥骨上ドレナージカテーテル
US6096030A (en) * 1997-09-23 2000-08-01 Pharmacyclics, Inc. Light delivery catheter and PDT treatment method
FR2777782B1 (fr) 1998-04-22 2001-05-18 Alexandre Marti Solution pour la preparation d'une substance pharmaceutique pour le diagnostic et/ou le traitement de lesions tissulaires
GB2360459B (en) 2000-03-23 2002-08-07 Photo Therapeutics Ltd Therapeutic light source and method
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
EP1312353A1 (en) 2001-11-16 2003-05-21 Ecole Polytechnique Federale De Lausanne (Epfl) Method for hair removal
AU2003258124A1 (en) * 2002-08-05 2004-02-23 Miravant Medical Technologies Light delivery catheter
EP1610865A4 (en) * 2003-03-14 2007-11-28 Light Sciences Oncology Inc LIGHT PRODUCTION DEVICE FOR INTRAVASCULAR USE
US7135034B2 (en) * 2003-11-14 2006-11-14 Lumerx, Inc. Flexible array
GB2408209A (en) * 2003-11-18 2005-05-25 Qinetiq Ltd Flexible medical light source
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
GB0724279D0 (en) 2007-12-12 2008-01-23 Photocure Asa Use
WO2009077960A1 (en) 2007-12-14 2009-06-25 Photoderma Sa Novel compounds useful in therapeutic and cosmetic methods
US20100016844A1 (en) * 2008-07-21 2010-01-21 Patel Jr Manoj B Transilluminating foley catheter to facilitate prostate and bladder surgery
GB0823472D0 (en) 2008-12-23 2009-01-28 Photocure Asa Product
JP2012529451A (ja) 2009-06-11 2012-11-22 フォトキュア エイエスエイ ５−アミノレブリン酸を含む固体組成物
DK2440199T3 (en) 2009-06-11 2016-05-17 Photocure Asa Semi-solid preparations, and pharmaceutical products
EP2563446A1 (en) * 2010-04-30 2013-03-06 Abbott Cardiovascular Systems Inc. Improved balloon catheter exhibiting rapid inflation and deflation
WO2011161220A1 (en) 2010-06-23 2011-12-29 Photocure Asa Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent
JP5991970B2 (ja) 2010-07-09 2016-09-14 フォトキュア エイエスエイ 光力学的治療または光力学的診断で使用する乾燥組成物および当該乾燥組成物を含む装置
US10357661B2 (en) 2011-09-30 2019-07-23 Percuvision, Llc Medical device and method for internal healing and antimicrobial purposes
US9249086B2 (en) 2012-08-03 2016-02-02 Photocure Asa Carboxylic acid ALA esters
US20140067024A1 (en) * 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
CN203598366U (zh) * 2013-12-16 2014-05-21 薛晓英 一种前列腺癌放疗使用的直肠内气囊
WO2015160064A1 (ko) * 2014-04-18 2015-10-22 부경대학교산학협력단 산광형 광섬유를 포함하는 프로브, 그 제조 방법 및 응용
CN203971207U (zh) * 2014-07-07 2014-12-03 陆改玲 一种激光治疗装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496271A (en) * 1990-09-14 1996-03-05 American Medical Systems, Inc. Combined hyperthermia and dilation catheter
WO2015006309A1 (en) * 2013-07-10 2015-01-15 Christoph Scharf Devices and methods for delivery of therapeutic energy

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI812839B (zh) * 2019-02-25 2023-08-21 日商大塚電子股份有限公司 光動力治療裝置及光動力治療裝置用卡匣盒
WO2021160751A1 (de) * 2020-02-14 2021-08-19 Albert-Ludwigs-Universität Freiburg Katheter mit antimikrobieller wirkung zur verhinderung der adhäsion
WO2021216605A1 (en) * 2020-04-20 2021-10-28 Cern Corp Vaginal light therapy devices and methods for using them
WO2023151768A1 (de) * 2022-02-09 2023-08-17 Richard Wolf Gmbh Bestrahlungsvorrichtung für die photodynamische therapie

Also Published As

Publication number Publication date
KR102666387B1 (ko) 2024-05-14
GB201522398D0 (en) 2016-02-03
PL3389778T3 (pl) 2022-10-10
EP3389778B1 (en) 2022-08-24
RU2018124869A3 (zh) 2020-03-10
RU2018124869A (ru) 2020-01-20
JP6860571B2 (ja) 2021-04-14
BR112018012182A2 (pt) 2018-11-27
DK3389778T3 (da) 2022-09-12
CN108778413B (zh) 2020-09-15
BR112018012182B1 (pt) 2023-11-28
CA3008555A1 (en) 2017-06-22
EP3389778A1 (en) 2018-10-24
AU2016369404A1 (en) 2018-07-12
CA3008555C (en) 2024-05-14
ES2926984T3 (es) 2022-10-31
KR20180095587A (ko) 2018-08-27
JP2018538077A (ja) 2018-12-27
AU2016369404B2 (en) 2021-09-30
RU2736406C2 (ru) 2020-11-16
US11565123B2 (en) 2023-01-31
CN108778413A (zh) 2018-11-09
WO2017103105A1 (en) 2017-06-22
US20200276450A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
US11565123B2 (en) Device for photodynamic treatment
JP5753573B2 (ja) 光活性化薬物療法のための方法および装置
JP3648555B2 (ja) カラム状環境を照射する改良された光線治療用装置
CA2182010C (en) Photochemical ablation of gastro-intestinal tissue
WO2014079972A1 (en) Device for photodynamic treatment
JP2005531336A (ja) 体内の微生物を弱化および／または死滅させるために可視光を用いる装置および方法
AU750633B2 (en) Improved method for targeted topical treatment of disease
JP2009535116A (ja) 光ワンドおよびバルーンカテーテル
Panjehpour et al. Light sources and delivery devices for photodynamic therapy in the gastrointestinal tract
JP2006271831A (ja) 医療用治療装置およびその装置の使用方法
US20220062654A1 (en) Apparatus and method for irradiating inside an object
JPH07144026A (ja) 光免疫療法による癌治療装置
US20180221679A1 (en) Catheter assembly and components thereof
Spinelli et al. Laserchemotherapy of tumours: clinical aspects

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHOTOCURE ASA, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GJOERSVIK, TORE;GODAL, ASLAK;REEL/FRAME:046190/0423

Effective date: 20180613

Owner name: PHOTOCURE ASA, NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TRITEQ LTD.;REEL/FRAME:046419/0675

Effective date: 20170221

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION